Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...

Opinion: McDermott, Will & Emery's Byron Kalogerou and Meredith Cullen Schwartz say demand in the anti-obesity market and new ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Eli Lilly’s stock has hit a 52-week low at $697.35, nosediving over 10% this past week, which has investors holding their ...

If approved, LMTX has the potential to become the first orally available disease-modifying therapy (DMT) in the UK.

Buoyed by new results from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's ...

Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.

That's why Veeva Systems should remain a leader in its niche and deliver excellent returns over the long run. It's a top stock to buy and hold for the next two decades.

The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.

Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

Weight loss drugs such as semaglutide, found in Ozempic and Wegovy, are tied to a 40% reduced risk of an Alzheimer's disease diagnosis. On Wednesday, a study in Nature suggested that a vaccine for ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.